Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Growth Opportunities in the Pharmaceutical Contract Manufacturing Organization Market - Global Forecast to 2024 - ResearchAndMarkets.com

December 18, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Dec 18, 2019--

The “Growth Opportunities in the Global Pharmaceutical Contract Manufacturing Organization Market (CMO) - Forecast to 2024” report has been added to ResearchAndMarkets.com’s offering.

This research service covers these technology trends with case examples of how some CMOs are ahead of the curve in adopting these technologies.

This study also covers the global market for pharmaceutical contract manufacturing for Active Pharmaceutical Ingredient (API) and Finished Dosage Form (FDF) manufacturing. It provides a comprehensive and critical analysis of subsectors, including generic APIs, novel APIs, HPAPIs, solid dosage forms, and injectable dosages. The study also examines top developed and emerging national markets, challenges in each of these markets, and hidden opportunities.

For example, in the US, where generic drug penetration is heavy at almost 80% and China, India, Russia, and Mexico where levels are as high as 90%, the CMO market has reached saturation and, therefore, CMOs can explore opportunities in lifecycle management of legacy products and redesigning synthesis routes to create high-tech generics.

Traditionally, CMOs have thrived by aggregating demand and delivering benefits of economies of scale. However, with the fading era of blockbuster drugs dispensed to large patient pools and shift to precision medicine, focus on niche indications, and increased R&D in biologics, pharma sponsors are increasingly turning to CMOs as strategic partners instead of contractors. Sponsors are looking for partnerships to not only append their existing capacity and get access to new markets but also to mitigate risk and bring overhaul in manufacturing technologies. Consequently, safety, efficacy, and product quality are outweighing cost-saving considerations.

CMOs are also stepping up to the growing demand by investing in containment technology to meet HPAPI demand, introducing distributed manufacturing to take manufacturing closer to the patient, and adopting continuous manufacturing and digitization of processes. For example, CMOs are partnering with third-party vendors for layered analytics with the aim of optimizing processes, introducing preventive maintenance, and making supply chains transparent.

This study also captures sponsors’ outlook for outsourcing by-products and by stage of drug lifecycle and the new engagement models being sought. In conjunction with the opportunities in product selection and manufacturing technologies, the study also has a detailed discussion on opportunities in the packaging segment in the light of new serialization requirements, track-and-trace solutions designed to reduce to counterfeit medicine, primary and secondary packaging to meet regional and local regulatory requirements, as well as opportunities to collaborate with CROs for new drug development.

The study also discusses the impact of ongoing consolidation, profiles of leading CMOs, key CMOs to watch for, and, most importantly, the interest of private equity firms in the segment.

Key Issues Addressed

Key Topics Covered:

1. Executive Dashboard

2. Market Overview

3. Market Dynamics

4. Revenue Forecast

5. Revenue Forecast - API

6. Revenue Forecast - FDF

7. Revenue Forecast - US

8. Revenue Forecast - Germany

9. Revenue Forecast - UK

10. Revenue Forecast - France

11. Revenue Forecast - Italy

12. Revenue Forecast - Spain

13. Revenue Forecast - Scandinavia

14. Revenue Forecast - Benelux

15. Revenue Forecast - India

16. Revenue Forecast - China

17. Revenue Forecast - Japan

18. Competitive Landscape

19. Key Collaboration Agreements in the Contract Manufacturing Market

20. Growth Opportunities

21. The Last Word - Strategic Considerations for Staying on the Growth Trajectory

22. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/stj46k

View source version on businesswire.com:https://www.businesswire.com/news/home/20191218005362/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 12/18/2019 07:09 AM/DISC: 12/18/2019 07:09 AM